at Benzinga.com (Dec 30, 2014)
Dendreon (DNDN +1.2%) preliminary adjusted FQ4 net product revenues +5% Q/Q to $81.6M vs consensus of $83.66M. Community sales hit record, with urology +25%, oncology +4%. Community accounts represent 71% of total sales, up from 58% in Q4 2011. Dendreon benefits from the increased use of its Provenge prostate cancer drug in community oncology and urology settings. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 18, 2014)
at Zacks.com (Nov 11, 2014)
at CNBC.com (Nov 10, 2014)
at Zacks.com (Nov 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs